BREAKING STUDY: Nattokinase Breaks Down SPIKE PROTEIN, AMYLOID MICROCLOTS, BLOOD CLOTS, and SHRINKS ARTERIAL PLAQUE

We assembled DECADES of evidence to uncover the powerful MULTI-TARGET EFFECTS of nattokinase:

- Degrades spike protein
- Breaks down harmful amyloid proteins
- Dissolves abnormal amyloid microclots
- Breaks down fibrin blood clots
- Boosts the body’s natural clot-dissolving system
- Shrinks arterial plaque
- Lowers blood pressure
- Reduces blood-clotting factors and platelet clumping

Our new paper, “Proteolytic Targets and Clinical Benefits of Oral Nattokinase: Spike Protein and Amyloid Degradation, Fibrinolysis, and Cardiovascular Risk Reduction,” was produced through a collaboration between The Wellness Company and the McCullough Foundation.

It represents one of the most comprehensive evaluations of nattokinase to date, uniquely integrating its proteolytic, cardiovascular, pharmacokinetic, amyloid, and spike-protein literature into a single paper.

After oral dosing, nattokinase-related activity shows up in human blood and changes clotting and clot-breakdown markers within hours.

Three independent labs have now shown that nattokinase-related enzymes can BREAK DOWN SPIKE PROTEIN in vitro—including purified nattokinase itself.

At higher doses, human imaging studies reported about a 36% SHRINKAGE in carotid artery plaque—suggesting the effective range may begin around 6,000 FU/day.

Randomized human trials also show modest BLOOD-PRESSURE reductions with nattokinase, with pooled decreases of about 3.5 mmHg systolic and 2.3 mmHg diastolic.

And in long-term population studies, higher natto intake was associated with a 25% LOWER RISK of cardiovascular death and a 32% LOWER RISK of stroke death.

Nattokinase has been well tolerated across human studies, with no notable adverse events reported across six randomized trials. Even 10,800 FU/day for 12 months was used in a large observational cohort without reported excess bleeding.

This inexpensive, orally available enzyme holds immense promise for cardiovascular risk reduction in the post-COVID era.

It now deserves large-scale clinical testing for cardiovascular risk reduction and other post-vaccination injury applications.

We plan to launch some of these studies shortly.

@twc_health @McCulloughFund @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly